
Repligen (RGEN) Stock Forecast & Price Target
Repligen (RGEN) Analyst Ratings
Bulls say
Repligen demonstrated strong financial performance in 4Q24, with total orders increasing by 11% both sequentially and year-over-year, and total orders for the full-year 2024 up by 9%. The company's revenue growth across all product segments, particularly in CDMO and capital equipment, highlights a robust momentum with sequential revenue increases of 20% and 30% respectively. Additionally, Repligen successfully expanded its adjusted gross margin by 140 basis points while maintaining disciplined cost control measures, indicating a solid foundation for continued profitability and growth.
Bears say
Repligen faces significant headwinds due to a slowdown in purchasing from small biotechs, which could lead to revenue declines within that sector. The company has downgraded its financial guidance twice, contributing to investor skepticism regarding its ability to provide conservative forward estimates amidst worsening visibility in customer inventory levels and spending plans. Additionally, concerns over potential delays in product launches, particularly related to technology shortages, and the transition of its long-standing CEO have introduced further uncertainty to Repligen's future performance.
This aggregate rating is based on analysts' research of Repligen and is not a guaranteed prediction by Public.com or investment advice.
Repligen (RGEN) Analyst Forecast & Price Prediction
Start investing in Repligen (RGEN)
Order type
Buy in
Order amount
Est. shares
0 shares